Novavax (NVAX)
(Delayed Data from NSDQ)
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Zacks News
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
What's in Store for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $140.69, moving +1.78% from the previous trading session.
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
by Zacks Equity Research
Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $111.15, moving +1.07% from the previous trading session.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
The Zacks Analyst Blog Highlights: Etsy, TMobile US, Anthem, Novavax and Southwest Gas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Etsy, TMobile US, Anthem, Novavax and Southwest Gas
Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight
by Tirthankar Chakraborty
Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).
Coronavirus to Cast a Pall Over Q2 Earnings: 5 Stocks to Stand Out
by Tirthankar Chakraborty
It will be prudent to invest in companies from the tech, healthcare and utility sectors, which are expected to have suffered less compared to others in Q2.
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals
by Zacks Equity Research
Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.
Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Company News for Jul 8, 2020
by Zacks Equity Research
Companies In The News Are: WMT, NVAX, DOCU, REGN.
Novovax Up on $1.6B Federal Funding for Coronavirus Program
by Zacks Equity Research
Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.
Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
FDA Issues Guidance for Coronavirus Vaccine Developers
by Kinjel Shah
Around a dozen companies are developing a vaccine for the deadly coronavirus disease.
Top Leveraged ETFs of Last Week
by Sanghamitra Saha
Leveraged gold miners and treasury ETFs gained last week despite a market crash.
The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP
Growth Investing Leads in 1H: 5 Top ETFs & Stocks
by Sweta Killa
Growth investing took a lead so far this year courtesy of massive money flowing into the economy.